Wpisz informacje, które znasz

zamknij

MANAGING DISCOVERY IN THE LIFE SCIENCES

A. Rea Philip

Oprawa:
TWARDA

Wydawca:
Cambridge University Press

ISBN:
9781107130906

441,00 PLN
Wysyłamy w 35 dni

Opis produktu

Philip A. Rea Professor of Biology and Rebecka and Arie Belldegrun Distinguished Director cofounded the Roy and Diana Vagelos Program in Life Sciences and Management at the University of Pennsylvania. A Fellow of the American Association for the Advancement of Science he has received several prestigious prizes and awards for his pioneering research on membrane transporters and his creative science teaching including the Presidents Medal of the Society for Experimental Biology and a Lindback Foundation Award for Distinguished Teaching.Addresses in roughly equal measure the science and management behind several recent marketable biomedical innovations.Key to biomedical innovation is scientific discovery and its translation into marketable products. This book addresses the link between life sciences discoveries and their dependence on the investordriven market system through indepth considerations of the challenges that both scientists and managers must face in the pharmaceutical and medical device industries.Key to biomedical innovation is scientific discovery and its translation into marketable products. This book addresses the link between life sciences discoveries and their dependence on the investordriven market system through indepth considerations of the challenges that both scientists and managers must face in the pharmaceutical and medical device industries.In this book distinguished scholars Philip A. Rea Mark V. Pauly and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities the cultures within and between academic and corporate entities and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies they consider the fundamental economic underpinnings of investordriven discovery management not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.Preface: 1. Discoveries now and then: shifting incentives and expectations Mark V. Pauly Philip A. Rea and Lawton R. Burns: 2. Pharma trends: not what they seem Kyle Myers and Mark V. Pauly: 3. Profit maximizing drug firms: models and myths Vicki Chen and Mark V. Pauly: Transitional note: introduction to the case studies: 4. The Statins: cholesterols penicillins Philip A. Rea: 5. ACE inhibitors: kidney clamps snake venoms and peptidomimetics Alec Ren and Philip A. Rea: 6. Angioplasty: catheters guidewires and balloons Simon Basseyn Sourav Bose Lawton R. Burns and Chris Groskaufmanis: 7. Hepatitis C

Wymiary: 235 mm 158 mm 29 mm 1010 gr

Dodaj recenzję

Zaloguj sie, aby móc dodać swoją recenzję.

Kontakt

mail: prus@prus24.pl

telefon: (22) 826-18-35

Copyright © 2001-2021 Główna Księgarnia Naukowa im. B. Prusa. Wszelkie prawa zastrzeżone.
Home   /   Informacje   /   Kontakt
Projekt i realizacja:
MDA.pl